Novigenix
Switzerland-based biotech company focused on Immuno-Transcriptomic oncology solutions
Novigenix has raised €22M across 2 funding rounds from 1 investor, most recently a Grant round in Apr 2025. Based in Lausanne, Switzerland; active in Healthtech. Data as of 28 Oct 2026.
Lausanne, Switzerlandnovigenix.com ↗
Total raised
€22M
€21,800,000
Funding rounds
2
Investors
1
distinct backers
Active since
2022-12
latest 2025-04
Funding by year
EUR raised per yearNovigenix — funding by year — interactive chart.
Data table
| Novigenix — funding by year | |
|---|---|
| 2022 | €20M |
| 2025 | €1.8M |
Signals
High confidenceRaise-next likelihood21
base rate 45% for Grant
- ▼ Past typical raise window
- ▼ Down/flat last round
- ▼ Low backer re-investment
Exit likelihood9
base rate 11% (2+ rounds)
- ▼ No recent equity round (debt-only or quiet)
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
2 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-04-04 | Grant | €1.8M | European Union (EU) research initiative | View deal → |
| 2022-12-02 | Series B | €20M | — | View deal → |
Investors
1Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
- Climeworks€919MSwitzerland · Cleantech
Global coverage: FundingData